<DOC>
	<DOCNO>NCT02805023</DOCNO>
	<brief_summary>Evaluate feasibility autologous cell preparation compose mixture cell enrich endothelial progenitor cell ( EnEPCs ) multipotent adult hematopoietic stem/progenitor cell ( HSPC ) ( BGC101 ) , treatment patient suffer peripheral arterial disease ( PAD ) critical limb ischemia ( CLI ) respond optimal pharmacological treatment control risk factor and/or revascularization failure , option revascularization treatment .</brief_summary>
	<brief_title>Assessing Feasibility BGC101 Treatment PAD &amp; CLI</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Have time ability complete study comply instruction . 2 . Capable understand purpose study content inform consent form 3 . Age &gt; 18 Male nonpregnant , nonlactating female 4 . At least one clinical diagnostic indication CLI : Clinical assessment Rutherford 45 Rest pain Nonhealing ischemic ulcer Minor tissue loss 5 . At least one hemodynamic indicator severe peripheral arterial occlusive disease : Ankle brachial index ( ABI ) &lt; 0.45 Toe brachial index ( TBI ) &lt; 0.4 TcPO2 &lt; 40mmHg A poor candidate standard revascularization treatment option peripheral arterial disease due ( 1 ) unfavorable anatomy ( e.g . small vessel disease major vessel stenosis/obstruction ) OR ( 2 ) continue presence small vessel microvasculature ) disease six week revascularization ( perform part standard care ) base patency treat vessel ( ) . Patients meet follow criterion eligible study . 1 . Concurrent therapy , Investigator 's opinion , would interfere evaluation safety efficacy study medication . 2 . Treatment investigational product within last 6 month enrollment active study involve use investigational device drug . 3 . Presence condition circumstance , judgment investigator , might increase risk patient decrease chance obtain satisfactory data achieve objective study . 4 . Based clinician opinion prognosis major amputation ( knee ) within 4 week assessment visit 5 . Lack femoral artery blood flow 6 . Based clinician opinion inability perform intramuscular injection case sever skin lesion , severe edema morbid obesity 7 . Blood transfusion precede 4 week ( exclude potential nonautologous cell harvest blood ) 8 . Heart failure ( NYHA 34 ) 9 . Hgb Less 9gm 10 . Myocardial infarction , brain infarction , uncontrolled myocardial ischemia persistent severe heart failure ( EF &lt; 25 % ) precede 3 month 11 . Significant valvular disease valve replacement ( base medical record ) 12 . Renal failure ( eGFR &lt; 30 , Chronic Kidney Damage Stage 45 ) 13 . Liver function test three time normal upper limit ( AST , ALT , ALP , GGT , LDH ) . 14 . Abnormal coagulation test ( PT ( INR ) &gt; 2 ) 15 . Pregnant lactate woman entry study 16 . People unwilling agree use acceptable method contraception condom screen study prevent pregnancy chronic infectious disease ( HIV1 , HIV2 , HBV , HCV ) 17 . Malignancy within precede 3 year , except BCC 18 . Concurrent acute infectious disease septicemia 19 . Chronic infectious disease ( HIV1 , HIV2 , Hepatitis viruses B C ) 20 . Immunodeficiency syndrome 21 . Cytotoxic drug treatment 22 . Inability communicate ( may interfere clinical evaluation patient ) 23 . Patient unlikely available followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>